Radoslav Mladenov
Aachen, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Fucosylation and Sialylation of Fc-Fragment of anti-Tumour Necrosis Factor Alpha Antibodies do not Influence Their Immunogenicity in Monocyte-Derived Dendritic Cells.
Journal: Journal of Crohn's & colitis
Published: February 25, 2021
Elimination of different leukaemia subtypes using novel CD89-specific human cytolytic fusion proteins.
Journal: British journal of haematology
Published: October 20, 2017
Human MAP Tau Based Targeted Cytolytic Fusion Proteins.
Journal: Biomedicines
Published: April 21, 2017
Fine Tuning Antibody Conjugation Methods using SNAP-tag Technology.
Journal: Anti-cancer agents in medicinal chemistry
Published: August 03, 2016
CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo.
Journal: Oncotarget
Published: March 14, 2016
Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Journal: Cancer letters
Published: November 18, 2015
A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
Journal: International journal of cancer
Published: September 04, 2015
Fully human MAP-fusion protein selectively targets and eliminates proliferating CD64(+) M1 macrophages.
Journal: Immunology and cell biology
Published: August 16, 2015
Targeting CD64 mediates elimination of M1 but not M2 macrophages in vitro and in cutaneous inflammation in mice and patient biopsies.
Journal: mAbs
Published: July 29, 2015
Novel angiogenin mutants with increased cytotoxicity enhance the depletion of pro-inflammatory macrophages and leukemia cells ex vivo.
Journal: Cancer immunology, immunotherapy : CII
Published: June 25, 2015
The Fc-alpha receptor is a new target antigen for immunotherapy of myeloid leukemia.
Journal: International journal of cancer
Published: January 30, 2015
Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy.
Journal: mAbs
Published: December 18, 2014
Last Updated: 09/26/2026